Navigation Links
ARIUS announces second quarter fiscal 2008 financial results
Date:7/11/2008

nts, short-term investments and net working capital of $5,635,365, $6,825,190 and $9,088,712, respectively. The Company currently believes that it has adequate financial resources to continue into the fourth quarter of fiscal 2008 based on planned research and development expenditures and operating costs.

About ARIUS

ARIUS is a biotechnology company discovering and developing the next wave of antibody therapeutics. Established in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM), that rapidly identifies and selects antibodies based on their functional ability to affect disease. This antibody generation engine has enabled ARIUS to assemble a portfolio of more than 500 antibody candidates. In addition to the antibodies it is developing in-house, ARIUS has ongoing partnerships with key biotechnology and drug development companies. ARIUS is listed on the TSX under the symbol "ARI". For further information, visit http://www.ariusmabs.com

Financial Information to Follow:

ARIUS RESEARCH INC.

(A DEVELOPMENT STAGE COMPANY)

INTERIM BALANCE SHEETS

(Unaudited)

-------------------------------------------------------------------------

May 31, November 30,

2008 2007

$ $

-------------------------------------------------------------------------

Assets

Current assets:

Cash and cash equivalents 8,543,124 5,635,365

Short-term investments - 6,825,190

Receivables 185,672 230,126

Refundable tax credits 600,000 400,000

Prepaid expenses
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ARIUS presents new findings for anti-cancer antibody programs at AACR
2. ARIUS announces first quarter fiscal 2008 financial results
3. ARIUS 2008 Annual and Special Meeting of Shareholders
4. ARIUS recognized for entrepreneurial excellence
5. ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
6. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
7. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
8. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
9. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
10. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
11. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Baylor Research Institute (BRI) at Dallas ... in Phoenix, AZ , today announce an ... for patients with a broad range of cancers. Aligning the ... trials and access to technology to drive the development of ... across Baylor Scott & White Health,s 49 hospitals ...
(Date:5/21/2015)... Specialty Pharmacy Times has completed its ... BPA Worldwide as a business publication member. As ... for Specialty Pharmacy Times based on business/distribution, demographics ... member of BPA Worldwide, Specialty Pharmacy Times shows ... the most reliable, unequaled data,” said Chris Hennessy, ...
(Date:5/21/2015)... San Francisco, CA (PRWEB) May 21, 2015 ... microbiome sequencing, has announced a partnership with PicnicHealth, ... records for patients. Participants diagnosed with Inflammatory Bowel ... as well as a complementary uBiome research kit. ... Summer 2014. , For more ...
(Date:5/21/2015)... W. R. Grace & Co. (NYSE: ... Germany has received good manufacturing practice (GMP) certification ... Pharmaceutical Excipient Council (IPEC) Foundation. , ... FP brand of pharmaceutical grade excipient silica gels ... Bay, Maryland (USA) and Sorocaba, Brazil locations. The ...
Breaking Biology Technology:Precision Medicine Collaboration to Increase Options for Cancer Patients 2Precision Medicine Collaboration to Increase Options for Cancer Patients 3Precision Medicine Collaboration to Increase Options for Cancer Patients 4Specialty Pharmacy Times Joins BPA Worldwide 2uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2
... Improvement in Overall Survival -- First Active Immunotherapy for ... Presented at Plenary Session at Upcoming AUA Annual Meeting ... 9:00 AM ET -SEATTLE, April 14 Dendreon Corporation ... pivotal Phase 3 IMPACT study of PROVENGE(R) (sipuleucel-T) in ...
... Particle (VLP) Vaccine Candidate Based on the 1918 Spanish ... Flu and Highly Pathogenic H5N1 Bird FluROCKVILLE, Md., ... Novavax, Inc. (Nasdaq: NVAX ) ... H1N1 virus-like particle (VLP) vaccine based on the 1918 ...
... Calif., April 14 WaferGen Biosystems, Inc. (OTC ... genetic analysis systems, today announced that it has ... preferred shares in the company,s wholly owned Malaysian ... private financing placement with total gross proceeds of ...
Cached Biology Technology:PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study 2PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study 3PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study 4NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains 2NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains 3NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains 4NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains 5WaferGen Announces Signing of Private Financing 2WaferGen Announces Signing of Private Financing 3WaferGen Announces Signing of Private Financing 4
(Date:4/27/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... first week of May, 2015 and will be fulfilling ... Gino Pereira , Chief Executive Officer ... as Wocket® enters the consumer market. We would like ...
(Date:4/20/2015)... , April 20, 2015 ...   Glenbeigh Records Management (GRM), Ireland,s ... with Dubai Islamic Bank. Having built up an impressive track ... now a leading player within the records management sector in ... expects to double is GCC staffbase and employ a further ...
(Date:4/13/2015)... April 13, 2015 According ... "Global Biometrics Market Forecast & Opportunities, 2020", the global ... of around 14% till 2020. The biometrics market ... scale implementation and review of biometric management systems. ... new products with greater efficiency, are resulting in ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... in California,s Yolo Bypass provide,an all-you-can-eat bug buffet ... the sea. That,s according to a new report,detailing ... fish,in harvested rice fields earlier this year, resulting ... state,s rivers. The report, provided to the ...
... leading scientists for discussions about the causative agents ... diseases of humans, including malaria, amoebic dysentery, sleeping ... Cell Biology of Eukaryotic Pathogens Symposium takes place ... environment for scientific discussions centered on current research ...
... hear relies on hair cells, sensory receptors that mechanically amplify ... channel. Although the transduction channel was characterized more than 30 ... components. A new study in The Journal of ... identification of this mystery channel. Recent studies have ...
Cached Biology News:For fish and rice to thrive in Yolo Bypass, 'just add water' 2For fish and rice to thrive in Yolo Bypass, 'just add water' 3
... Kit (E-22013) provides,researchers with a sensitive ... in solution. This fluorescence-based assay can ... (Figure 1). The assay,measures lysozyme activity ... labeled to such a degree that ...
... m7G(5')ppp(5')G (Cap Analog) is used for the ... in vitro transcription reactions. Substitution of cap ... GTP in an in vitro transcription reaction ... structure into a large fraction of the ...
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
... is a modified cap analog in which ... is replaced with OCH3. Because of this ... transcription with the remaining hydroxyl group thus ... As a result, unlike transcripts synthesized with ...
Biology Products: